Sitryx Therapeutics, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announces the successful completion of an additional financing, raising a further $39 million (£32 million), following the $30 million Series A financing announced in October 2018. Source: Sitryx press release 27/9/2023